IRIS
CIMADAMORE, Alessia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 5.416
NA - Nord America 2.502
SA - Sud America 1.460
EU - Europa 1.271
AF - Africa 194
OC - Oceania 5
Continente sconosciuto - Info sul continente non disponibili 2
AN - Antartide 1
Totale 10.851
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 2.717
US - Stati Uniti d'America 2.368
BR - Brasile 1.159
CN - Cina 913
HK - Hong Kong 589
VN - Vietnam 507
IT - Italia 332
RU - Federazione Russa 228
FR - Francia 221
DE - Germania 211
KR - Corea 181
AR - Argentina 116
BD - Bangladesh 104
IN - India 101
TG - Togo 68
MX - Messico 61
GB - Regno Unito 59
ID - Indonesia 58
EC - Ecuador 57
IQ - Iraq 43
CA - Canada 38
TR - Turchia 38
ZA - Sudafrica 36
AT - Austria 32
FI - Finlandia 32
CO - Colombia 31
PY - Paraguay 28
CL - Cile 26
NL - Olanda 26
PL - Polonia 26
JP - Giappone 23
ES - Italia 21
PK - Pakistan 20
VE - Venezuela 18
UA - Ucraina 16
UZ - Uzbekistan 16
EG - Egitto 15
MA - Marocco 14
TN - Tunisia 14
IE - Irlanda 13
KE - Kenya 13
LT - Lituania 13
JO - Giordania 12
SA - Arabia Saudita 12
PE - Perù 11
UY - Uruguay 11
AE - Emirati Arabi Uniti 9
DZ - Algeria 9
SE - Svezia 9
AZ - Azerbaigian 8
JM - Giamaica 6
KZ - Kazakistan 6
NP - Nepal 6
HN - Honduras 5
IL - Israele 5
LB - Libano 5
PH - Filippine 5
CR - Costa Rica 4
CZ - Repubblica Ceca 4
DO - Repubblica Dominicana 4
ET - Etiopia 4
MD - Moldavia 4
SY - Repubblica araba siriana 4
TW - Taiwan 4
AL - Albania 3
AM - Armenia 3
AO - Angola 3
BH - Bahrain 3
BO - Bolivia 3
GR - Grecia 3
GT - Guatemala 3
IR - Iran 3
KW - Kuwait 3
NI - Nicaragua 3
OM - Oman 3
QA - Qatar 3
SN - Senegal 3
SV - El Salvador 3
AU - Australia 2
BE - Belgio 2
BW - Botswana 2
HU - Ungheria 2
LK - Sri Lanka 2
LV - Lettonia 2
LY - Libia 2
NZ - Nuova Zelanda 2
PR - Porto Rico 2
PS - Palestinian Territory 2
PT - Portogallo 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
AD - Andorra 1
AQ - Antartide 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BY - Bielorussia 1
CD - Congo 1
CH - Svizzera 1
CI - Costa d'Avorio 1
CW - ???statistics.table.value.countryCode.CW??? 1
Totale 10.826
Salva come PNG Salva come JPEG
Città #
Singapore 721
Hong Kong 579
Beijing 380
Council Bluffs 362
San Jose 307
Boardman 200
Ashburn 190
Lauterbourg 190
Hefei 183
Ho Chi Minh City 180
Seoul 178
Frankfurt am Main 149
Hanoi 123
Los Angeles 111
Redondo Beach 91
São Paulo 91
Dallas 88
The Dalles 82
Buffalo 74
Lomé 68
Ogden 60
New York 44
Santa Clara 43
Milan 40
Rio de Janeiro 40
Guayaquil 30
Rome 29
Mexico City 28
Nuremberg 28
Belo Horizonte 27
Brasília 24
Helsinki 23
Mumbai 23
Porto Alegre 23
Naples 22
Curitiba 21
Biên Hòa 19
Orem 19
Remanzacco 19
Boston 18
Da Nang 18
Ispra 18
Haiphong 17
Hyderabad 17
Warsaw 17
Tokyo 16
Vienna 16
Amsterdam 15
Brooklyn 15
Campinas 14
Chicago 14
Johannesburg 14
Montreal 14
Ribeirão Preto 14
Salvador 14
Codroipo 13
Columbus 13
Quito 13
Tashkent 13
Baghdad 12
Goiânia 12
Thái Bình 12
Amman 11
Denver 11
Dublin 11
Jakarta 11
Maceió 11
Munich 11
Nairobi 11
Santo André 11
Shanghai 11
Ankara 10
Atlanta 10
Duque de Caxias 10
Franca 10
Guangzhou 10
Hải Dương 10
Istanbul 10
Xi'an 10
Asunción 9
Cape Town 9
Carapicuíba 9
Fortaleza 9
London 9
Thái Nguyên 9
Tunis 9
Buenos Aires 8
Bắc Giang 8
Cabo Frio 8
Chennai 8
Dhaka 8
Guarulhos 8
Manaus 8
Medellín 8
Montevideo 8
Phoenix 8
Poplar 8
Baku 7
Bogotá 7
Caracas 7
Totale 5.599
Salva come PNG Salva come JPEG
Nome #
News in the classification of WHO 2022 bladder tumors 177
End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer 134
SIUrO best practice recommendations to optimize BRCA 1/2 gene testing from DNA extracted from bone biopsy in mCRPC patients (BRCA Optimal Bone Biopsy Procedure: BOP) 112
The uropathologist of the future: getting ready with intelligence for the prostate cancer tsunami 108
Apalutamide or enzalutamide in castration-sensitive prostate cancer: a number needed to treat analysis 106
Novel Therapeutic Strategies for Metastatic Prostate Cancer Care 104
A gender-related dichotomy in bladder cancer 86
Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high-grade non-muscle-invasive urothelial bladder cancer 84
Biological and therapeutic implications of FGFR alterations in urothelial cancer: A systematic review from non-muscle-invasive to metastatic disease 83
Nectin-4 Positivity in Genitourinary Malignancies: A Systematic Review 82
Giant cell carcinoma of the urinary bladder: Clinicopathologic analysis and oncological outcomes 80
Follow-up of the Urethra and Management of Urethral Recurrence After Radical Cystectomy: A Systematic Review and Proposal of Management Algorithm by the European Association of Urology-Young Academic Urologists: Urothelial Carcinoma Working Group 79
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications 78
Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems 77
Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies 77
Prognostic Significance of Programmed Cell Death-1, Programmed Cell Death-Ligand 1, Programmed Cell Death-Ligand 2, and Fibroblast Growth Factor Receptor 3 mRNA Expression in Bladder Cancer 76
Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer 76
Conceptual Analogies Between Multi-Scale Feeding and Feedback Cycles in Supermassive Black Hole and Cancer Environments 73
Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: A systematic review and network meta-analysis 73
The Prognostic Significance of Histological Subtypes in Patients with Muscle-Invasive Bladder Cancer: An Overview of the Current Literature 72
How To Report the Minor Component of a High-grade Pattern in Radical Prostatectomy Specimens: Time To Abandon the “Tertiary” Terminology? 71
Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial 70
Epigenetic modulations and lineage plasticity in advanced prostate cancer 70
Activity of chemokines in prostate and renal tumors and their potential role as future therapeutic targets 69
An update on investigational therapies that target STAT3 for the treatment of cancer 69
Agent-Based Learning Model for the Obesity Paradox in RCC 69
Patients ask and pathologists answer: ten questions around prostate cancer grading 68
Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors 68
Re: Outcomes of Biopsy Grade Group 1 Prostate Cancer Diagnosis in the Danish Population 68
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A) 68
Efficacy of Different Bacillus of Calmette-Guérin (BCG) Strains on Recurrence Rates among Intermediate/High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): Single-Arm Study Systematic Review, Cumulative and Network Meta-Analysis 67
Histopathology of Prostate Cancer and its Precursors 67
Added Clinical Value of Whole-mount Histopathology of Radical Prostatectomy Specimens: A Collaborative Review 67
Treating prostate cancer by antibody-drug conjugates 66
PreImplantation Factor immunohistochemical expression correlates with prostate cancer aggressiveness 65
Frequent Telomerase Reverse Transcriptase Promoter and Fibroblast Growth Factor Receptor 3 Mutations Support the Precursor Nature of Papillary Urothelial Hyperplasia of the Urinary Bladder 65
Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: Focus on sequences and prognostic factors 65
Targeted treatment of renal cell carcinoma 65
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B) 65
An evaluation of current prostate cancer diagnostic approaches with emphasis on liquid biopsies and prostate cancer 63
Are liver nested stromal epithelial tumors always low aggressive? 62
Adjuvant therapy in renal cell carcinoma: Is it the right strategy to inhibit VEGF? 62
TNM staging towards a personalized approach in metastatic urothelial carcinoma: What will the future be like?-a narrative review 61
Bone targeting agents in patients with metastatic prostate cancer: State of the art 60
Intraductal Carcinoma of the Prostate: Pathogenesis and Molecular Perspectives 59
Re: George J. Netto, Mahul B. Amin, Eva M. Compérat, et al. Prostate Adenocarcinoma Grade Group 1: Rationale for Retaining a Cancer Label in the 2022 World Health Organization Classification. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.015 59
Uropathologists During the COVID-19 Pandemic: What Can Be Learned in Terms of Social Interaction, Visibility, and Social Distance 59
Chromophobe Renal Cell Carcinoma Aggressiveness and Immuno-oncology Therapy: How to Distinguish the Good One from the Bad One 59
Clinical utility of checkpoint inhibitors against metastatic bladder cancer: overcoming challenges to find a way forward 59
Questioning the prognostic role of BAP-1 immunohistochemistry in malignant pleural mesothelioma: A single center experience with systematic review and meta-analysis 59
An insight on novel molecular pathways in metastatic prostate cancer: A focus on ddr, msi and akt 59
Designing novel immunocombinations in metastatic renal cell carcinoma 58
Re: Gillian Vandekerkhove, Werner J. Struss, Matti Annala, et al. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer. Eur Urol 2019;75:667–75: How Does Circulating DNA Reach the Blood Stream? 58
An update on immunotherapy in uro-oncology 58
Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non-muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysis 58
Spectrum of incipient (or precursor) lesions in the mucosa of the seminal vesicles 58
Staging and reporting of renal cell carcinomas 58
Epigenetic modifications and modulators in prostate cancer 58
Re: Friederike Haidl, David Pfister, Axel Heidenreich. Re: Prostatic Artery Embolization in the Treatment of Localized Prostate Cancer: A Bicentric Prospective Proof-of-Concept Study of 12 Patients. Mordasini L, Hechelhammer L, Diener PA, et al. J Vasc Interv Radiol 2018;29:589–97. Eur Urol 2018;74:525–6: Could Morphologic Changes in Periprostatic Arteries Have an Influence on Prostatic Artery Embolization? 58
Biomarkers of aggressiveness in genitourinary tumors with emphasis on kidney, bladder, and prostate cancer 58
Grading of Chromophobe Renal Cell Carcinoma: Do We Need It? 57
Prostate cancer in 2021: Novelties in prognostic and therapeutic biomarker evaluation 57
PARP Inhibitors and Radiometabolic Approaches in Metastatic Castration-Resistant Prostate Cancer: What’s Now, What’s New, and What’s Coming? 57
The Role of Artificial Intelligence in the Diagnosis and Prognosis of Renal Cell Tumors 57
Digital real-time microscopy of ex-vivo tissues: A novel strategy to control surgical accuracy 56
pT1 high-grade bladder cancer: histologic criteria, pitfalls in the assessment of invasion, and substaging 56
The most effective but largely ignored target for prostate cancer early detection and intervention 55
Re: Timothy D. Jones, Liang Cheng. Histologic Grading of Bladder Tumors: Using Both the 1973 and 2004/2016 World Health Organization Systems in Combination Provides Valuable Information for Establishing Prognostic Risk Groups. Eur Urol 2021;79:489–91 54
Renal Cell Carcinoma: genomic landscape and clinical implications 54
Quick steps toward precision medicine in renal cell carcinoma 54
Towards a new WHO classification of renal cell tumor: What the clinician needs to know-a narrative review 54
OUTCOMES OF DIFFERENT PATTERN OF SEMINAL VESICLE INVASION IN PATIENTS TREATED WITH RADICAL PROSTATECTOMY 53
Tumors of the Urinary System and Male Genital Organs: 2022 World Health Organization Classification and Multidisciplinarity 53
Editorial: Emerging biomarkers in genitourinary tumors 53
Pathology without microscope: From a projection screen to a virtual slide 53
The impact of lymphovascular invasion in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma: An extensive updated systematic review and meta-analysis 53
The molecular characteristics of non‐clear cell renal cell carcinoma: What’s the story morning glory? 53
Surgical checklist adherence across urology expertise levels impacts transurethral resection of bladder tumour quality indicators 53
Narrative review of prostate cancer grading systems: Will the Gleason scores be replaced by the grade groups? 53
Molecular classification of bladder urothelial carcinoma using nanostring‐based gene expression analysis 53
Digital and computational transition in the pathology lab: when did it start? 53
T1 bladder carcinoma with variant histology: pathological features and clinical significance 53
Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor? 53
Digital pathology and COVID-19 and future crises: pathologists can safely diagnose cases from home using a consumer monitor and a mini PC 52
Emerging Molecular Technologies in Genitourinary Tumors 52
Incorporating Prognostic Biomarkers into Risk Assessment Models and TNM Staging for Prostate Cancer 52
Myoid gonadal stromal tumours are characterised by recurrent chromosome-level copy number gains: molecular assessment of a multi-institutional series 52
Resistance to systemic agents in renal cell carcinoma predict and overcome genomic strategies adopted by tumor 52
Combining radiotherapy with immunocheckpoint inhibitors or CAR-T in Renal Cell Carcinoma 52
Surgical pathology of cystic renal cell carcinomas: is there an overestimation of malignancy? 52
Re: Scott Wilkinson, Huihui Ye, Fatima Karzai, et al. Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2021.03.009: Focus on Intraductal Carcinoma of the Prostate 51
Inguinal bladder hernia with lipomatosis of the bladder wall: A potential clinical pitfall for cancer 51
BRCA-associated protein 1 (BAP1) and miR-31 combination predicts outcomes in epithelioid malignant pleural mesothelioma 50
Exploring small extracellular vesicles for precision medicine in prostate cancer 50
Re: Theo van der Kwast, Fredrik Liedberg, Peter C. Black, et al. International Society of Urological Pathology Expert Opinion on Grading of Urothelial Carcinoma. Eur Urol Focus. In press. https://doi.org/10.1016/j.euf.2021.03.017: Focus on Our Personal Recollections and Observations 50
Risk Classification of Bladder Cancer by Gene Expression and Molecular Subtype 50
Predictive biomarkers for immunotherapy in the treatment of advanced urothelial carcinoma: Where we stand and where we go 49
Re: Maria Chiara Sighinolfi, Bernardo Rocco's Words of Wisdom re: EAU Guidelines: Prostate Cancer 2019. Mottet N, van den Bergh RCN, Briers E, et al. https://uroweb.org/guideline/prostate-Cancer/. Eur Urol 2019;76:871 49
Lesson from the COVID-19 pandemic: pathologists need to build their confidence on working in a digital microscopy environment 49
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer 49
Totale 6.471
Salva come PNG Salva come JPEG
Categoria #
all - tutte 61.743
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 61.743
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/2023628 0 0 0 0 0 0 1 2 512 9 60 44
2023/2024411 25 9 17 10 36 24 10 22 88 112 29 29
2024/20253.489 74 226 38 51 63 162 97 106 341 449 584 1.298
2025/20267.029 502 740 1.030 924 807 625 604 292 258 441 687 119
Totale 11.557